Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 18, 2017
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP ProductionClinical Outcomes Research Showing a Correlation between NT-proBNP Response and Health-related Quality of LifeData Presented at Heart Failure Society of...
Aug 15, 2017
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related Quality of Life DUBLIN, Irelan...
Aug 8, 2017
Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8 million, provides funding to advance diverse pipelineInitiated, with Roche, the global Phase 2 PASADENA st...
Aug 1, 2017
DUBLIN, Ireland, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the second quarter and first six months of 2017 on August 8, 2...
Jul 5, 2017
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson's diseaseProthena to receive $30 million milestone payment under collaboration agreement with Roche DUBLIN, Ireland, July 05, 2017 (GLOBE...
Jun 12, 2017
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Wagner Zago, PhD, as Chief Scientific Officer (CSO). Dr. Zago, wh...
May 16, 2017
DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Sarah Noonberg, MD, PhD, as Chief Medical Officer. Dr. Noonberg ...
May 9, 2017
Net cash used in operating and investing activities was $40.2 million in the first quarter; quarter-end cash and restricted cash position of $510.6 million, including net proceeds of $150.3 million raised through March 2017 public equity offering, provides funding to advance R&D pipelineCompleted enro...
May 2, 2017
DUBLIN, Ireland, May 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the first quarter of 2017 on May 9, 2017 after the close of the U.S. financial ...
Apr 26, 2017
DUBLIN, Ireland, April 26, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Deutsche Bank 42nd...
Apr 2, 2017
All dose levels of PRX002/RG7935 found to have an acceptable safety and tolerability profile, meeting the primary objective of this studyRobust central nervous system (CNS) penetration demonstrated by a dose-dependent increase in PRX002 levels in cerebrospinal fluid (CSF), and mean concentrati...
Mar 9, 2017
Investor webcast planned for April 2, 2017 at 9:00 AM EDT to discuss Phase 1b study results  Prothena and Roche to co-host symposium on alpha-synuclein pathology and non-motor manifestations in Parkinson's disease on March 31, 2017 at 5:15 CET DUBLIN, I...
Mar 3, 2017
DUBLIN, Ireland, March 03, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has sold 2,700,000 of its ordinary shares at a price to the public of $57...
Mar 2, 2017
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has commenced a registered underwritten public offering of 2,700,000 of its ordinary shar...
Feb 14, 2017
Net cash used in operating and investing activities was $41.1 million in the fourth quarter and $133.9 million for the full year 2016; year-end cash and restricted cash position of $391 million supports advancement of clinical pipeline         Pre...
Page:
...
Next Last
 
= add release to Briefcase